The aim of this study is to produce short, individual reports on the current and future regulatory status and processes which are of relevance to the 19 HBM4EU Priority Substance Groups; and policy briefs for each of the nine substance groups in the first list of HBM4EU Priority Substance Groups. The 19 individual reports shall identify the current legislative status of the chemical substances under both EU chemicals legislation and any relevant multi-lateral agreements, including any ongoing or planned regulatory processes. Within these processes, the relevant entry points for the EEA to submit HBM4EU data will be highlighted. The nine policy briefs shall outline the progress made so far under the HBM4EU project by reviewing available human biomonitoring evidence, the ability of HBM4EU to produce new human biomonitoring evidence and where such human biomonitoring data can be used by policy makers and chemical risk managers.
RPA's Covid-19 CO2 Emissions Savings Covid-19 has affected all of humanity in unprecedented ways. The global pandemic has driven a global economic crisis that has […]
RPA's study on the selection of risk management options for the Nickel Institute has now been published Building on its positive experiences gained in relation to the EU RMOA process, the Nickel Institute contracted RPA to undertake […]